


## NNRT-IN-1

Cat. No.:	HY-149928
CAS No.:	2925364-09-4
Molecular Formula:	C <sub>28</sub> H <sub>22</sub> N <sub>6</sub> O <sub>3</sub>
Molecular Weight:	490.51
Target:	HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	NNRTIs-IN-1 is a potent non-nucleoside reverse transcriptase inhibitor featuring significantly anti-resistance efficacy. NNRTIs-IN-1 inhibits the wild-type HIV-1 and five mutant strains with EC <sub>50</sub> s in the nanomolar range. NNRTIs-IN-1 displays favorable pharmacokinetic properties <sup>[1]</sup> .
<b>In Vitro</b>	NNRTIs-IN-1 (compound 8r) inhibits the wild-type HIV-1 (EC <sub>50</sub> =2.3 nM) and five mutant strains, K103N (EC <sub>50</sub> =8 nM), E138K (EC <sub>50</sub> =6 nM), double-digit potency against L100I (EC <sub>50</sub> =13 nM), Y181C (EC <sub>50</sub> =29 nM), and Y188L (EC <sub>50</sub> =52 nM) <sup>[1]</sup> . NNRTIs-IN-1 shows no apparent inhibitory effect on CYP1A2, CYP2D6, CYP3A4-T, and CYP3A4-M with IC <sub>50</sub> values over 50 μM, and exhibits extremely weak activity toward RPV-sensitive CYP2C9 and CYP2C19 subtypes (IC <sub>50</sub> =18.5 and 23.6 μM) <sup>[1]</sup> . NNRTIs-IN-1 displays very weak inhibition of hERG (IC <sub>50</sub> >40 μM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	NNRTIs-IN-1 (1 mg/kg; i.v.) exhibits a favorable half-life of 3.66 h and a mean residence time (MRT) of 3.75 h, and the maximal concentration (C <sub>max</sub> ) is up to 431 ng/mL <sup>[1]</sup> . NNRTIs-IN-1 (5 mg/kg; p.o.) exhibits a half-life of 5.18 h, a MRT of 5.21 h, a C <sub>max</sub> value of 616 ng/mL, and the oral bioavailability (F) of 31.19% <sup>[1]</sup> . NNRTIs-IN-1 (p.o.) is well tolerated at a dose of 2 g/kg <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Sang YL, et, al. Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy. *J Med Chem.* 2023 Apr 13;66(7):4755-4767.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA